The Role of Thymoma and Thymic Hyperplasia as Prognostic Risk Factors for Secondary Generalisation in Adults with Ocular Myasthenia Gravis: A Systematic Narrative Review
Source : https://pubmed.ncbi.nlm.nih.gov/38046270/
This review provides evidence for the consideration of thymectomy early after thymomatous OMG diagnosis to prevent GMG conversion. As the review did not collect enough evidence to support the influence...
This review provides evidence for the consideration of thymectomy early after thymomatous OMG diagnosis to prevent GMG conversion. As the review did not collect enough evidence to support the influence of thymic hyperplasia on OMG conversion, further research is required.
Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence
Source : https://pubmed.ncbi.nlm.nih.gov/38059203/
The terminal complement C5 inhibitor ravulizumab was engineered from the humanized monoclonal antibody eculizumab to have an extended half-life and duration of action. It binds to human terminal complement protein...
Ravulizumab, a terminal complement C5 inhibitor, demonstrated rapid and sustained efficacy with a favorable safety profile in treating anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, supported by its extended dosing interval and targeted mechanism of action.
Zilucoplan: First Approval
Source : https://pubmed.ncbi.nlm.nih.gov/38093160/
Zilucoplan (Zilbrysq ® ) is a subcutaneously administered macrocyclic peptide inhibitor of complement component 5 (C5 inhibitor) being developed by UCB for the treatment of generalised myasthenia gravis (gMG). Zilucoplan...
Zilucoplan (Zilbrysq®), a C5 inhibitor, has received approvals in Japan, the USA, and the EU for treating generalized myasthenia gravis in adults who are anti-AChR antibody positive and have inadequate response to other therapies, marking significant milestones in its development.
Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study
Source : https://pubmed.ncbi.nlm.nih.gov/38810600/
Eculizumab was effective in reducing disease burden and was well tolerated in adolescents with refractory AChR antibody-positive gMG.
Eculizumab was effective in reducing disease burden and was well tolerated in adolescents with refractory AChR antibody-positive gMG.
![Efgartigimod Alfa (Vyvgart): CADTH Reimbursement Recommendation [Internet]](https://static-content-prd.skipta.com/public/skipta/skipta-post/2024-07/file0L7BvG "Efgartigimod Alfa (Vyvgart): CADTH Reimbursement Recommendation [Internet]")
Efgartigimod Alfa (Vyvgart): CADTH Reimbursement Recommendation [Internet]
Source : https://pubmed.ncbi.nlm.nih.gov/38564544/
Treatment with Vyvgart is expected to cost approximately $63,200 to $94,800 per patient per course, or $298,304 to $447,456 per patient per year, depending on patient weight and assuming 4.72...
CADTH recommends reimbursing Vyvgart for adult patients with generalized myasthenia gravis (gMG) who meet specific criteria: diagnosed with class II to IV gMG, tested positive for anti-acetylcholine receptor antibodies, and have a Myasthenia Gravis Activities of Daily Living (MG-ADL) scale score of at least 5. Reimbursement conditions include...